Bachelet Ido, Munitz Ariel, Moretta Alessandro, Moretta Lorenzo, Levi-Schaffer Francesca
Department of Pharmacology, School of Pharmacy, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
J Immunol. 2005 Dec 15;175(12):7989-95. doi: 10.4049/jimmunol.175.12.7989.
Mast cell-mediated responses are likely to be regulated by the cross talk between activatory and inhibitory signals. We have screened human cord blood mast cells for recently characterized inhibitory receptors expressed on NK cells. We found that IRp60, an Ig superfamily member, is expressed on human mast cells. On NK cells, IRp60 cross-linking leads to the inhibition of cytotoxic activity vs target cells in vitro. IRp60 is constitutively expressed on mast cells but is down-regulated in vitro by the eosinophil proteins major basic protein and eosinophil-derived neurotoxin. An immune complex-mediated cross-linking of IRp60 led to inhibition of IgE-induced degranulation and stem cell factor-mediated survival via a mechanism involving tyrosine phosphorylation, phosphatase recruitment, and termination of cellular calcium influx. To evaluate the role of IRp60 in regulation of allergic responses in vivo, a murine model of allergic peritonitis was used in which the murine homolog of IRp60, LMIR1, was neutralized in BALB/c mice by mAbs. This neutralization led to a significantly augmented release of inflammatory mediators and eosinophilic infiltration. These data demonstrate a novel pathway for the regulation of human mast cell function and allergic responses, indicating IRp60 as a candidate target for future treatment of allergic and mast cell-associated diseases.
肥大细胞介导的反应可能受激活信号和抑制信号之间的相互作用调节。我们在人脐血肥大细胞中筛选了自然杀伤细胞(NK细胞)上最近鉴定出的抑制性受体。我们发现,免疫球蛋白超家族成员IRp60在人肥大细胞上表达。在NK细胞上,IRp60交联导致体外对靶细胞的细胞毒性活性受到抑制。IRp60在肥大细胞上组成性表达,但在体外被嗜酸性粒细胞蛋白主要碱性蛋白和嗜酸性粒细胞衍生神经毒素下调。免疫复合物介导的IRp60交联通过涉及酪氨酸磷酸化、磷酸酶募集和细胞钙内流终止的机制,导致IgE诱导的脱颗粒和干细胞因子介导的存活受到抑制。为了评估IRp60在体内调节过敏反应中的作用,我们使用了过敏性腹膜炎小鼠模型,其中通过单克隆抗体在BALB/c小鼠中中和IRp60的小鼠同源物LMIR1。这种中和导致炎症介质的释放显著增加和嗜酸性粒细胞浸润。这些数据证明了一种调节人肥大细胞功能和过敏反应的新途径,表明IRp60是未来治疗过敏和肥大细胞相关疾病的候选靶点。